Sumana Shashidhar
Stanford University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sumana Shashidhar.
The Journal of Infectious Diseases | 2005
Caroline Arber; Andrew BitMansour; Sumana Shashidhar; Sophia Y. Wang; Benjamin Tseng; Janice M. Brown
Invasive fungal infections are a leading cause of morbidity and mortality after myelotoxic chemotherapy or radiation exposure. The resulting depletion of myeloid precursors under these conditions appears to be the factor that limits approaches to accelerate immune reconstitution. In a murine model of myeloablation after radiation exposure, we demonstrated that highly purified common myeloid and granulocyte-monocyte progenitors (CMPs/GMPs) accelerated myeloid recovery and, thus, enhanced innate immunity as measured by survival after a lethal challenge with Aspergillus fumigatus. Of greatest significance was the demonstration that the protection afforded by CMPs/GMPs was not major histocompatibility complex restricted. Furthermore, the effect of CMP/GMP cellular therapy was additive with that of liposomal amphotericin B treatment. These observations greatly expand the potential donor pool and, thus, the clinical utility of CMP/GMP cellular therapy in patients with myeloid depletion.
Biology of Blood and Marrow Transplantation | 2011
Joanna Schaenman; Sumana Shashidhar; Chanu Rhee; Jonathan Wong; Shelly Navato; Ruby M. Wong; Dora Y. Ho; Sally Arai; Laura Johnston; Janice M. Brown
The reconstitution of immune function after hematopoietic cell transplant (HCT) plays an important role in the control of viral infections. Both donor and recipient cytomegalovirus (CMV) serostatus has been shown to contribute to effective immune function; however, the influence of a nonmyeloablative preparative (NMA) regimen using total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) on antiviral immune reconstitution has not yet been described. In 117 recipients of NMA HCT patients following ATG and TLI, not unexpectedly, CMV viremia was seen in approximately 60% of the seropositive patients regardless of donor serostatus, and recipient seropositivity significantly increased the odds of CMV viremia after transplant in a multivariate analysis. The administration of ATG and TLI resulted in a strikingly earlier viremia in the posttransplant period when compared to the previously reported timing of viremia following myeloablative preparative regimens, especially for transplant recipients who were seropositive for CMV with seronegative donors. Furthermore, early viremia in the setting of a CMV naïve donor was associated with a delay in functional antiviral control. These observations demonstrate the dynamic nature of immunity in relation to CMV antigen exposure in the complex environment resulting from NMA conditions where both donor and residual recipient immune response affect viral control.
Biology of Blood and Marrow Transplantation | 2011
Brile Chung; Dullei Min; Lukas W. Joo; Mark R. Krampf; Jing Huang; Yujun Yang; Sumana Shashidhar; Janice M. Brown; Eric P. Dudl; Kenneth I. Weinberg
The decreased ability of the thymus to generate T cells after bone marrow transplantation (BMT) is a clinically significant problem. Interleukin (IL)-7 and stem cell factor (SCF) induce proliferation, differentiation, and survival of thymocytes. Although previous studies have shown that administration of recombinant human IL-7 (rhIL-7) after murine and human BMT improves thymopoiesis and immune function, whether administration of SCF exerts similar effects is unclear. To evaluate independent or combinatorial effects of IL-7 and SCF in post-BMT thymopoiesis, bone marrow (BM)-derived mesenchymal stem cells transduced ex vivo with the rhIL-7 or murine SCF (mSCF) genes were cotransplanted with T cell-depleted BM cells into lethally irradiated mice. Although rhIL-7 and mSCF each improved immune reconstitution, the combination treatment had a significantly greater effect than either cytokine alone. Moreover, the combination treatment significantly increased donor-derived common lymphoid progenitors (CLPs) in BM, suggesting that transplanted CLPs expand more rapidly in response to IL-7 and SCF and may promote immune reconstitution. Our findings demonstrate that IL-7 and SCF might be therapeutically useful for enhancing de novo T cell development. Furthermore, combination therapy may allow the administration of lower doses of IL-7, thereby decreasing the likelihood of IL-7-mediated expansion of mature T cells.
Proceedings of the National Academy of Sciences of the United States of America | 2012
Antonia M. S. Müller; Sumana Shashidhar; Natascha J. Küpper; Holbrook Kohrt; Mareike Florek; Robert S. Negrin; Janice M. Brown; Judith A. Shizuru
Impaired immunity is a fundamental obstacle to successful allogeneic hematopoietic cell transplantation. Mature graft T cells are thought to provide protection from infections early after transplantation, but can cause life-threatening graft-vs.-host disease. Human CMV is a major pathogen after transplantation. We studied reactivity against the mouse homologue, murine CMV (MCMV), in lethally irradiated mice given allogeneic purified hematopoietic stem cells (HSCs) or HSCs supplemented with T cells or T-cell subsets. Unexpectedly, recipients of purified HSCs mounted superior antiviral responses compared with recipients of HSC plus unselected bulk T cells. Furthermore, supplementation of purified HSC grafts with CD8+ memory or MCMV-specific T cells resulted in enhanced antiviral reactivity. Posttransplantation lymphopenia promoted massive expansion of MCMV-specific T cells when no competing donor T cells were present. In recipients of pure HSCs, naive and memory T cells and innate lymphoid cell populations developed. In contrast, the lymphoid pool in recipients of bulk T cells was dominated by effector memory cells. These studies show that pure HSC transplantations allow superior protective immunity against a viral pathogen compared with unselected mature T cells. This reductionist transplant model reveals the impact of graft composition on regeneration of host, newly generated, and mature transferred T cells, and underscores the deleterious effects of bulk donor T cells. Our findings lead us to conclude that grafts composed of purified HSCs provide an optimal platform for in vivo expansion of selected antigen-specific cells while allowing the reconstitution of a naive T-cell pool.
Blood | 2008
Vu H. Nguyen; Sumana Shashidhar; Daisy S. Chang; Lena Ho; Neeraja Kambham; Michael H. Bachmann; Janice M. Brown; Robert S. Negrin
Blood | 2005
Andrew BitMansour; Thai M. Cao; Stephanie Chao; Sumana Shashidhar; Janice M. Brown
Blood | 2006
Vu H. Nguyen; Daisy Chang; Sumana Shashidhar; Michael H. Bachmann; Christopher H. Contag; Janice M. Brown; Robert S. Negrin
Blood | 2016
Isabelle T Nguyen; Sumana Shashidhar; Janice M. Brown
Blood | 2014
Nivedita Shankar Saxena; Jing Huang; Yujun Yang; Dullei Min; Carmencita Nicolas; Sumana Shashidhar; Janice M. Brown; Kenneth I. Weinberg
Biology of Blood and Marrow Transplantation | 2014
Janice M. Brown; Abraham Chang; Fu-ying Lee-Lam; Susanna K. Tan; Sumana Shashidhar